More Information on 'Energenesis Biomedical Co Ltd'

Visual Protein is a company that provides innovative products and services for research use, particularly in the fields of proteomics, immunology, and cytology. The company offers a range of products, including Western blot tools, protein quantification kits, and cell culture supplements. Their products are designed to facilitate research and development in these fields, with a focus on efficacy, reproducibility, and reliability. Visual Protein's product line includes specific kits such as the BlockPRO 1 Min Protein-Free Blocking Buffer and the Dual-Range BCA Protein Assay Kit, which are used for Western blotting, protein quantification, and other immunoassay applications. The company aims to support researchers worldwide with its products and services, and its staff is comprised of professionals with strong academic backgrounds, with over 90% holding a master's degree or above.

Announcements
Public Company (TWSE:6657)

About Energenesis Biomedical Co Ltd
Established in 2005, Visual Protein is dedicated to enhancing biological developments by providing innovative products and services for research use. Our greatest strength is our research and development capability. Most products developed by Visual Protein are more effective than those developed by famous international companies. Our expertise broadens research possibilities in proteomics, immunology, and cytology. In 2012, Visual Protein's founder expanded our mission by establishing Energenesis Biomedical, focusing on developing new drugs and medicines. In 2015, Energenesis Biomedical incorporated Visual Protein, elevating it as a key brand for research reagents and kits. For new drug development, Energenesis Biomedical employs a distinctive ENERGI platform centered around the purine-based compound ENERGI. Administration of ENERGI on cells can increase cellular energy (adenosine triphosphate, ATP). Extensive research shows a strong link between ATP levels and aging, neurodegenerative diseases, ischemic injuries, tumors, diabetes, and inflammatory bowel diseases. Our ongoing projects focus on new drugs for chronic wound care, alopecia, metabolic syndromes, inflammatory diseases, neurodegenerative diseases, and other areas. Through different formulations and dosages, we advance new drug research and development. Currently, the company is advancing several promising drugs through clinical trials, including ENERGI-F703DFU, a gel for treating diabetic foot ulcers in phase III trials in the USA and Taiwan, and ENERGI-F701 for alopecia, which has completed phase II trials. With its innovative technology and significant clinical trial advancements, Energenesis Biomedical achieved a major milestone by going public on the Taiwan Stock Exchange (TWSE: 6657) on June 12, 2023. Energenesis Biomedical is actively seeking global channel partners to expand our sales network for Visual Protein products and licensing partners for ENERGI platform assets. Our vision is to collaborate with our partners to provide unique and high-quality solutions for advanced science research and unmet medical demand.

Looking for Channel Partners in: